#France #Strasbourg #Domain Therapeutics #GPCR #Jean-Marie Cuillerot

Domain Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

A Major Addition to the Team
Domain Therapeutics has made headlines with the appointment of Jean-Marie Cuillerot, M.D., as its new Chief Medical Officer. This strategic move comes at a transformative time for the company, especially as it gears up for the Phase I/II development of DT-7012, a promising anti-CCR8 monoclonal antibody designed to deplete Treg cells. Based in Boston, Dr. Cuillerot brings an impressive wealth of experience in the pharma and biotech sectors, boasting a proven ability to convert innovation into clinical realities.

Dr. Cuillerot's Impressive Background
Before joining Domain, Dr. Cuillerot played a pivotal role at Bristol-Myers Squibb, where he was at the forefront of developing ipilimumab, which became the first approved immune checkpoint inhibitor for cancer treatment. His experience includes leading crucial Phase II and III trials across various indications while supporting regulatory submissions in Europe and the U.S.

At EMD Serono, he made significant contributions as Global Head of Clinical Development in Immuno-Oncology and later as Vice President of Clinical Immunotherapy. His leadership was instrumental in accelerating the clinical development of avelumab, achieving rare accolades, including the esteemed Merck CEO Award for his accomplishments.

Apart from his role at Domain, Dr. Cuillerot has held the position of Chief Medical Officer at various other biotech companies, including Acrivon and Agenus. His tenure at these institutions exemplifies his knack for expediting innovative therapies through early clinical phases and toward regulatory approvals.

A Vision for Progress
Sean A. MacDonald, the CEO of Domain Therapeutics, expressed his enthusiasm, stating, "We are thrilled to have someone of Dr. Cuillerot's caliber join our team. His extensive experience and proven history in the biotech industry makes him an ideal fit to help advance our pipeline as we pursue clinical proof of efficacy."

In his position, Dr. Cuillerot plans to leverage Domain’s solid foundation in G protein-coupled receptor (GPCR) biology to deliver groundbreaking treatments that address significant unmet medical needs.
"I am excited to join Domain. The company’s expertise in GPCR biology sets the stage for unique approaches to tackling medical challenges, particularly through our GPCR-targeting therapies that show high potential for transforming patient outcomes," Dr. Cuillerot shared. His collaborative spirit is expected to enhance the development of leading candidates such as DT-7012 and others, including DT-9081 and DT-9046.

Future Focus
As Domain Therapeutics continues to refine its strategies, Dr. Cuillerot's guidance will be critical in advancing clinical candidates through rigorous phases while pursuing significant value-creating milestones. The ongoing Phase I/II DOMISOL trial in Australia for DT-7012 illustrates the exciting path ahead for the company as it aims to redefine the landscape of immune system modulation.

About Domain Therapeutics
Domain Therapeutics is a clinical-stage biopharmaceutical firm that specializes in developing innovative therapeutic tactics that target GPCRs, a vital category of drug targets. With an ambitious pipeline, the company focuses on addressing unmet medical needs, particularly in the fields of immuno-oncology and inflammation. Their key programs highlight groundbreaking therapies, including a next-generation Treg-depleting anti-CCR8 antibody that is set to innovate treatment paradigms significantly.
For more information about their pioneering efforts and advancements, visit Domain Therapeutics.